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Mild cognitive impairmentAlzheimer's disease (AD) is a highly disabling progressive neurodegenerative disorder characterized by a
steadily growing number of patients, by the absence of a cure for the disease and by great difﬁculties in
diagnosing in the preclinical phase. Progresses in deﬁning the complex etiopathogenesis of AD consider
oxidative stress a core aspect as far as both AD onset and progression are concerned. However, clinical trials
of antioxidants in AD have brought conﬂicting conclusions. In this review, we report the main results of clin-
ical trials with antioxidants in mild cognitive impairment (MCI) and AD. Although available data do not war-
rant the doubtless use of antioxidants in AD, they are characterized by extremely poor comparability and the
absence of a substantial clinical beneﬁt of antioxidants in AD is not disproved to date. Furthermore, the role of
vascular damage that contributes to oxidative stress in AD should be addressed in testing antioxidant treat-
ments. This article is part of a Special Issue entitled: Antioxidants and Antioxidant Treatment in Disease.
© 2011 Elsevier B.V. All rights reserved.1. Introduction
Alzheimer's disease (AD), the most common cause of dementia in
elderly people, is characterized by progressive neurodegenerative
alterations that gradually reduce cognitive and functional abilities
of the affected subject. Loss of synapses and neurons as well as accu-
mulation of extracellular Aβ plaques and intraneuronal neuroﬁbrillary
tangles are the main hallmarks of AD brain. Aging is a major risk factor
for AD and estimates of the impact of aging world population continue
to grow, with 35.6 million people living with dementia worldwide in
2010, and a projection to 65.7 million by 2030 and 115.4 million by
2050 [1]. AD is also a highly disabling disorder with an estimated
11.2% of years lived with disability by over-60-year-old people [2] and
so it is becoming a public health priority in developing countries [3].
The impressive, steadily growing number of patients with AD, the
absence of a cure for the disease and the current difﬁculty in diagnosing
its preclinical phase constitute at the moment three major challenges
that render AD a unique social and medical issue. Since the time at
which Alois Alzheimer described what for many years has been a ‘sim-
ple’ case report, several steps have been taken in the past fewdecades to
address the pathophysiological mechanisms of the disease. Despite
remarkable progress in understanding AD pathogenesis, the search for
a cure against the disease is troublesome and frustrating, especially inants and Antioxidant Treatment
and Geriatrics, University of
lock C Floor 4, S. Andrea delle
: +39 075 578 3878.
rights reserved.light of its epidemiologic growing. This is due to a problematic combina-
tion of several factors, mostly related to the difﬁculty of moving from
bench to bedside. Most of the research on therapy for AD transfers
one chemical substance targeted on a single biological system to sub-
jects with age-modiﬁed biology, suffering from multimorbidity and
under polypharmacy: a single answer to a multifaceted puzzling prob-
lem. In other words, the ‘one alteration, one disease, one drug’ strategy
does not seem to work well in AD, a typical example of a complex mul-
tifactorial disease.
This is shown by the paramount example of the approved acetyl-
cholinesterase inhibitors (donepezil, rivastigmine, galantamine) as
anti-AD therapy. Their use is based on the decrease of cholinergic trans-
mission in the basal forebrain cholinergic neurons, but they havemainly,
if not only, symptomatic effects, with large inter-individual responses.
Symptomatic is also the effect of the approvedNMDA receptor antagonist
memantine. Several anti-AD strategies such as anti-amyloid and anti-tau
therapies, anti-mitochondrial dysfunction drugs and neurotrophins, are
under evaluation in RCTs of safety and efﬁcacy [4].
The free radical and oxidative stress theory of aging [5] suggests that
oxidative damage is amajor player in neuronal degeneration and several
studies have demonstrated that oxidative stress is an early occurring
condition in AD [6, 7]. So, the overall collected data have prompted
the performance of a number of trials aimed at exploring the efﬁcacy
of antioxidants in AD and in what is considered its preclinical form,
the mild cognitive impairment (MCI). Antioxidants are a group of
endogenous or exogenous molecules that “when present in low con-
centrations compared to that of an oxidizable substrate, signiﬁcantly
delays or inhibits the oxidation of that substrate” [8]. Antioxidants act
at the level of removing and scavenging reactive oxygen species
(ROS), scavenging ROS precursors, inhibiting ROS and other free radical
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eration. The natural antioxidant system can be subdivided in enzymatic
and non-enzymatic antioxidants. As opposed to chelating agents, that
are indirect antioxidants, the direct antioxidants are scavenging and
chain-breaking molecules represented mainly by the exogenous ascor-
bate (vitamin C), tocopherols/tocotrienols (vitamin E) and carotenoids.
Endogenous direct antioxidants include molecules such as glutathione,
uric acid and bilirubin.
2. Clinical trials with antioxidants in MCI and AD
Based on data derived from several observational and epidemiological
studies several compounds with antioxidant activity have been proposed
for prevention of cognitive decline [9] and treatment of MCI [10] or AD
[11].
In Table 1 the main clinical trials with antioxidants in MCI and AD
– ongoing or conducted in the last ﬁfteen years – are reported. For a
complete list of clinical trials with Ginkgo biloba please refer to Ref.
[71].
2.1. Vitamin E
Vitamin E, the most potent lipophilic chain-breaking antioxidant
[12], refers to eight different isoforms that belong to two categories,
four saturated analogs (α, β, γ, δ), tocopherols, and four unsaturated
analogs, tocotrienols [13]. Vitamin E bioavailability, metabolism and
plasma levels have been studied in humans and in AD, particularly as
α-tocopherol [14–16]. Vitamin E has been shown to cross the blood
brain barrier and to accumulate at therapeutic levels in the central ner-
vous system, where it is able to lower lipid peroxidation and β-amyloid
deposition [17]. It also rescues neuronal damage and β-amyloid deposi-
tion in the brain by reducing isoprostane levels [18].
Observational studies on dietary or supplemented vitamin E led to
conﬂicting results. The Cache County Study showed no beneﬁt or sig-
niﬁcant reduction in the risk for AD as far as vitamin C and E intake
are concerned [19] and similar observations were obtained in the
Washington-Heights-Inwood Columbia Aging study [20], the Age-
Related Eye Disease Study [21] and the Women's Health Study [22].
Morris et al. [23], instead, examined the relationship between use of
vitamin E and vitamin C and incident AD in a prospective study of
633 persons 65 years and older. After an average follow-up period
of 4.3 years, 91 of the sample participants were diagnosed with AD,
but none of the 27 vitamin E supplement users had AD (3.9 pre-
dicted) and none of the 23 vitamin C supplement users had AD (3.3
predicted) while there was no relation between Alzheimer disease
and use of multivitamins. Other positive results were obtained in
the Honolulu–Asia Aging Study [24], the Chicago Health and Aging
Project [25], the Nurses' Health Study [26], and the Rotterdam Study
[27]. Because of the scarce comparability and interpretation of results
due to lack of homogeneity and numerousness of tested groups as
well as to differences in study design, type and dose of supplement,
endpoint, conducting expensive randomized clinical trials on antiox-
idants has not been highly supported up to now [28].
Vitamin E was the ﬁrst antioxidant to have been tested in a large
placebo-controlled trial, performed on 341 patients with moderate
to severe AD [29]. Those treated with a daily dose of 2000 IU of vita-
min E for two years showed a signiﬁcant delay in AD progression and
in nursing home placement but no effect was observed on Mini-
Mental State Examination score at the end of the study.
Negative results were found in treating subjects with MCI with vita-
min E [30]. In this study, 769 subjects withMCI were randomly assigned
to receive 2000 IU of vitamin E daily or 10 mg of donepezil or placebo for
three years. At the end of the study 212 developed AD, with 16% conver-
sion rate per year. The hazard ratio indicating the probability of progres-
sion to AD in the vitamin E group was 1.02, not signiﬁcantly different
from that of donepezil (0.80). There were no signiﬁcant differences inthe rate of progression to AD between vitamin E and placebo groups at
any point, either considering all patients or the apolipoprotein E ε4 car-
riers. The secondary outcomemeasures of the study included changes of
cognition as assessed by MMSE, CDR sum of boxes, Global Deterioration
Scale, and modiﬁed ADAS-Cog which showed few weak signiﬁcant dif-
ferences in the vitamin E group compared with the placebo group.
The possible explanations of these frustrating results have been
identiﬁed by Brewer [31] as wrong dose, wrong timing, and unbal-
anced monotherapy.
Regarding the ﬁrst issue, Miller and colleagues suggest that doses
of vitamin E above 400 IU/day may increase mortality [32] while in a
dose-ranging study there was a linear trend between the dosage of
vitamin E and percent reduction in plasma F2-isoprostane concentra-
tions which reached signiﬁcance at doses of 1600 IU (35%±2%
pb0.035) and 3200 IU (49%±10% pb0.005) [33].
As far as timing of therapy is concerned, it might be far too late
starting an antioxidant therapy in patients with AD, in which a large
proportion of neurons is already destroyed; indeed the observation
of elevated isoprostanes levels in MCI [18] and the failure of vitamin
E treatment in subjects with MCI [30] suggest that even the treatment
in MCI and pre-AD might come too late.
The use of a single antioxidant is, from a biochemical point of
view, likely not to work due to the fact that vitamin E needs vitamin
C or other soluble electron acceptors for a better systemic removal
of ROS and for antioxidant regeneration, although frustrating results
of combination therapy with antioxidants in other diseases have
been published [34]. Other possible factors linked to ‘unbalanced
monotherapy’ [31] are the facts that one of the three α-tocopherol
unsaturated analogs, γ-tocopherol, might be inﬂuenced in its metab-
olism upon administration of α-tocopherol, and that the two tocoph-
erols appear to be differentially depleted and nitrated in AD patients
[35].
Two clinical trials with vitamin E are ongoing: the Prevention of
Alzheimer's Disease by Vitamin E and Selenium (PREADVISE) and
the TEAM-AD, a randomized, clinical Trial of vitamin E And Meman-
tine in Alzheimer's Disease.
The PREADVISE is a phase III RCT, started in May 2002 and it is
expected to enroll, until August 2012, 10,400 subjects amongmen previ-
ously involved in the prostate cancer prevention SELECT study. Subjects
will be either assigned to α-tocopherol 400 IU daily plus selenium
200 μg daily, α-tocopherol 400 IU plus placebo daily, selenium 200 μg
daily plus placebo or placebo onlywith the primary endpoint of assessing
the effects of the treatment on AD incidence within 7 to 12 years after
study commencement [clinicaltrials.gov NCT00040378].
In the TEAM-AD, 840 patients with mild to moderate AD under
stable treatment with acetylcholinesterase inhibitors will be assigned
to either α-tocopherol (1000 IU twice a day), memantine (10 mg
twice a day), α-tocopherol (1000 IU twice a day) plus memantine
(up to 10 mg twice a day) or matching placebo. The TEAM-AD started
in 2007 and patients are going to be treated for 3 years with a follow-
up period ranging from a minimum of one year to a maximum of four
years. This phase III trial has the ADCS-ADL inventory as primary end-
point and, as secondary outcome measures, the ADAS-cog, the MMSE
and the NPI (Neuropsychiatric inventory). The estimated study com-
pletion date is July 2012 [clinicaltrials.gov NCT00235716].
2.2. Flavonoids
Flavonoids are themost common group of polyphenolic compounds
in the human diet and are found ubiquitously in plants being present in
several fruits and vegetables, beverages like tea andwine, and seeds like
cocoa beans and grape seeds [36].
Flavonoids may be divided into several subclasses. Among them the
ﬂavanolmonomers, known as catechins, are found in high concentration
in the tea plant leaves. The major tea catechins include (−)-epicatechin
(EC), (−)-epigallocatechin (EGC), (−)-EC gallate (ECG) and (−)-EGC
Table 1
Summary of clinical trials with antioxidants in MCI and AD.
Compound Number of
subjects and
disease
Intervention Primary endpoint Main results Reference
Vitamin E 341 patients
with AD
Daily vitamin E 2000 IU, selegiline 10 mg,
vitamin E+selegiline or placebo for 2 years
Time to the occurrence of death,
institutionalization, loss of ability
to perform activities of daily living,
or severe dementia
Delays in the time to
institutionalization in
patients treated with
selegiline, vitamin E,
or both
[29]
Vitamin E 769 subjects
with MCI
Daily vitamin E 2000 IU, donepezil 10 mg, or
placebo for 3 years
Slowing of the rate of progression
from MCI to AD
No differences
among groups
[30]
Vitamin E 10,400 elderly
subjects
Vitamin E 400 IU+selenium 200 μg/day or
vitamin E 400 IU/day or selenium 200 μg/day
or placebo for 7–12 years
AD incidence Ongoing Clinicaltrials.gov
NCT00040378
Vitamin E 840 patients with
AD
Vitamin E 2000 IU+memantine 20 mg or
vitamin E 2000 IU or memantine 20 mg or
placebo for 3 years
ADCS-ADL Ongoing Clinicaltrials.gov
NCT00235716
Epigallo-
catechine
gallate
(EGCG)
50 patients
with AD
EGCG (increasing dose from 200 to 800 mg)
daily or placebo add on to donepezil for
18 months
ADAS-cog score Ongoing Clinicatrials.gov
NCT00951834
Resveratrol 330 subjects
with MCI
Resveratrol supplementation or caloric
restriction or omega-3 supplementation
or placebo for 6 months
ADAS-cog score Ongoing Clinicaltrials.gov
NCT01219244
Resveratrol 60 patients
with AD
Resveratrol with glucose and malate
supplementation or placebo for 1 year
ADAS-cog score Ongoing Clinicaltrials.gov
NCT00678431
Curcumin 34 patients
with AD
Curcumin 1 g daily or 3 g daily or placebo
for 6 months
MMSE scores or β-amyloid
plasma levels
No differences
among groups
[53]
Curcumin 22 patients
with AD and 11
controls
Curcumin 2 g daily or 4 g daily or placebo
for 6 months
Cognitive performance and
plasma CSF biomarkers
No differences
among groups
in a preliminary
analysis
[55]
Curcumin 26 patients
with AD
Curcumin 2 g daily or 3 g daily or placebo
for 60 days
Cognitive performance Ongoing Clinicaltrials.gov
NCT01001637
Curcumin 132 subjects
with MCI
Curcumin 180 mg daily or placebo for
18 months
Amyloid protein deposits
(as measured with FDDNP
PET imaging)
Ongoing, not yet
recruiting
Clinicatrials.gov
NCT01383161
Pramipexole 20 patients
with AD
Increasing dose (from 100 to 300 mg daily)
pramipexole for 24 weeks
Safety issues and effects on
cognitive performance
Ongoing Clinicaltrials.gov
NCT01388478
Latrepirdine 598 patients
with AD
Up to 20 mg latrepirdine or placebo for 26 weeks ADAS-cog scores, MMSE scores,
ADCS-ADL scores
No differences
between groups
[60]
Latrepirdine 1050 patients
with AD
Latrepirdine or placebo add on to donepezil
for 1 year
ADAS-cog and ADCS-ADL scores Ongoing Clinicaltrials.gov
NCT00829374
Ubiquinone,
vitamin E
or lipoic acid
75 patients
with AD
Coenzyme Q 400 mg or vitamin E 800 IU+
vitamin C 200 mg+α-lipoic acid 600 mg or
placebo t.i.d. for 4 months
Changes in CSF biomarkers Completed Clinicaltrials.gov
NCT00117403
Lipoic acid 100 patients with
AD
Lipoic acid 600 mg+ﬁsh oil 3 g for 18 months ADAS-cog and ADL Ongoing Clinicaltrials.gov
NCT01058941
Idebenone 450 patients
with AD
Placebo (1 year)+90 mg idebenone (1 year) or
90 mg idebenone (2 years) or 120 mg idebenone
(2 years) t.i.d.
ADAS-total score Improvement of
ADAS-tot scores
after 6 months at
the highest dosage
[70]
Idebenone 300 patients
with AD
Idebenone 30 mg, 90 mg or placebo t.i.d.
for 6 months
ADAS-total score Improvement of
ADAS-tot scores
after 6 months at
the highest dosage
[71]
Idebenone 536 patients
with AD
Idebenone 120 mg or 240 mg or 360 mg or
placebo t.i.d. for one year
ADAS-cog and CGIC scores No differences
among groups
[72]
Ginkgo biloba 3069 cognitively
healthy elderly
and subjects
with MCI
Ginkgo biloba 120 mg b.i.d. or placebo for
6 years (median)
Incidence of dementia, AD or rate
of progression to AD in subjects
with MCI
No effects on the
incidence of
dementia, AD or
rate of progression
from MCI to AD
[76]
Ginkgo biloba 2854 subjects with
memory
complaints
Ginkgo biloba 120 mg b.i.d. or placebo for 5 years Rate of progression
to AD in MCI patients
Ongoing [77]
Nutriceutical
containing N-acetyl
cysteine
800 subjects with
early memory loss
N-acetyl cysteine 600 mg+methylcobalamin
2 mg+L-methylfolate calcium 6 mg for
12 weeks
Quality of life assessed by Quality
of Life Alzheimer's disease scale
Ongoing Clinicaltrials.gov
NCT01370954
Nutriceutical
containing N-acetyl
cysteine
60 subjects with
MCI
N-acetyl cysteine (NAC; 600 mg), folic acid
(400 μg), Vitamin B12 (6 μg), Vitamin E
(as alpha-tocopherol; 30 IU),
S-adenosylmethionine (SAM; 400 mg), and
acetyl-L-carnitine (ALCAR; 500 mg).or placebo
for one year
Cognitive and behavioral test
scores used in the trial.
Completed Clinicaltrials.gov
NCT00903695
(continued on next page)
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Table 1 (continued)
Compound Number of
subjects and
disease
Intervention Primary endpoint Main results Reference
Nutriceutical
containing
N-acetyl
cysteine
300 subjects with
MCI or AD
N-acetyl cysteine (NAC; 600 mg), folic acid
(400 μg), Vitamin B12 (6 μg), Vitamin E
(as alpha-tocopherol; 30 IU),
S-adenosylmethionine (SAM; 400 mg),
and acetyl-L-carnitine (ALCAR; 500 mg).
for one year
Cognitive improvement or
maintenance of cognitive
performance
Ongoing Clinicaltrials.gov
NCT01320527
ADAS: Alzheimer Disease Assessment Scale (Cog: cognitive score).
ADCS-ADL: Alzheimer's Disease Cooperative Study—Activity of Daily Living.
CGIC: Clinical Global Impression of Change.
MMSE: Mini Mental State Examination.
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effect of superoxide anions and hydroxyl radicals is related to the pres-
ence of the C-ring gallate group and the A ring [37]. EGCG is the most
active antioxidant among the tea catechins and, like the other catechins,
is also able to up-regulate superoxide dismutase, catalase, glutathione
peroxidase and tocopherol [38]. Plasma concentration of polyphenols is
very low compared to other antioxidants, so it is probable that the biolog-
ical effects of dietary polyphenols aremore related to their ability inmod-
ulating cell-signaling pathways and inﬂammatory responses rather than
to a direct antioxidant activity [39]. Prospective cohort studies on ﬂavo-
noids intake and risk of developing dementia led to inconsistent results
[27, 40–44]. Since high blood levels of homocysteine may be increased
in AD and hyperhomocysteinemia may contribute to disease patho-
physiology by vascular and direct neurotoxic mechanisms [45], the
effect of an antioxidant beverage rich in polyphenols on the plasmatic
levels of homocysteine in patients with AD has been recently evaluated.
To this purpose Morillas-Ruiz et al. performed a multicenter, random-
ized, double-blind controlled clinical trial of polyphenols supplementa-
tion in 100 subjects [46]. Twenty-four patients with initial AD, 24
patients with moderate AD as well as 52 controls were randomly
assigned to assume either an antioxidant beverage rich in polyphenols
or an identical placebo beverage (200 ml/day each) for 8 months. The
fasting plasma concentrations of homocysteine measured before and
after the ingestion of the beverage showed higher baseline levels in
the group with AD than in patients with mild AD and in the control
group. The antioxidant drink vs. placebo drink attenuated homocys-
teine increase in the control group and AD, especially in the moder-
ate phase, but no other effects where achieved.
There is an ongoing phase II/III RCT on 50 patients with early AD
already under donepezil treated with EGCG vs. placebo for 18 months
recruitment phase. The primary endpoint of the study is the ADAS-
cog score at study end [clinicaltrials.gov NCT00951834].
2.3. Resveratrol
Resveratrol belongs to a class of polyphenolic compounds called
stilbenes and it is found in grapes and red wine. It has shown antiox-
idant and antiinﬂammatory properties in vitro and cardioprotective
and longevity effects in animal models [47]. A double-blind, placebo-
controlled, crossover investigation on young healthy subjects showed
an increase in cerebral blood ﬂow but no short term effect in cognitive
performances [48]. Resveratrol is under investigation versus placebo in
a RCT using liquid resveratrol with glucose and malate as a dietary sup-
plement delivered in grape juice in 60 AD patients with the primary
endpoint of assessing ADAS-cog scores at regular intervals up to
1 year after study commencement [clinicaltrials.gov NCT00678431].
Another multi-interventional clinical trial in MCI proposed resveratrol
in one arms of intervention. The study, that should be completed in
2012, aims at evaluating modiﬁcation on ADAS-Cog [clinicaltrials.gov
NCT01219244].2.4. Curcumin
Curcumin is the principal curcuminoid in turmeric, a yellow spice
derived from Curcuma longa, member of the ginger family indigenous
in South Asia. Curcumin has several beneﬁcial properties — including
anti-inﬂammatory, antioxidant, and chemotherapeutic [49] and it was
shown to dose-dependently inhibit the formation of β-amyloid ﬁbrils
from Aβ40 and Aβ42, the two major species of β-amyloid deposits in
the brain [50]. Due to its antioxidant properties, its positive safety results
aswell as its beneﬁts on cognitive performances shown in animalmodels
of AD [51, 52] some clinical trials have been conducted with curcumin in
dementia. In a RCT versus placebo conducted in 34 patientswith AD trea-
ted with 1 g or 3 g curcumin per day or placebo, no differences in MMSE
scores or inβ-amyloid plasma levelswere shownafter 6 months [53]. In a
preliminary analysis of the results of a RCT vs. placebo of phase II type
using 2 g or 4 g curcumin in mild and moderate AD for 24 weeks, no sig-
niﬁcant changes in cognitive performance or in plasma CSF biomarkers
among groups were shown [54, 55]. Other clinical trials with curcumin
are active, one phase II trial of 2 g or 3 g/day of curcumin vs. placebo in
patientswithmoderate to severe AD treated for 60 days [clinicaltrials.gov
NCT01001637] and one in subjects with MCI treated or not with curcu-
min for eighteen months with the aim of evaluating amyloid deposition
in the brain with FDDNP-PET scan [clinicaltrials.gov NCT01383161].
2.5. Pramipexole
Pramipexole and other dopamine agonists have been recently
demonstrated to have neuroprotective effects in vitro and in vivo
possibly through antioxidant effects, as incubation with pramipexole
in cell cultures increased cellular levels of glutathione (GSH), and glu-
tathione peroxidase (GSH-Px) and catalase activities [56]. A phase II
trial is now ongoing in 20 patients with AD with R-pramipexole
twice a day for a total dose of 100 mg/day. After 4 weeks, the dose
will be doubled and after another 4 weeks patients will be treated with
300 mg R-pramipexole per day that will be maintained for the subse-
quent 16 weeks. There is no placebo arm and the primary endpoints
are safety issues and effects on cognitive performance, while secondary
outcome measures are lowering of oxidative stress as assessed by CSF
isoprostanes levels before and after treatment as well as changes in ce-
rebral glucose metabolism as assessed by PET scan before and after
treatment. The estimated study completion date is April 2014 [clinical-
trials.gov NCT01388478].
The development of latrepirdine (Dimebon) as an anti-AD strategy
was based on its safety data as anti-histaminic and on his beneﬁcial ef-
fects on mitochondria [57] whose damage increases a status of oxidative
stress [58]. Dimebon has also been shown to modulate mitochondrial
function in cells at nanomolar concentration, to stabilize mitochondria
membrane potential and to improve neuron survival under oxidative
stress condition, reinforcing the role of Dimebon as a mitochondrion-
targeted drug [59]. In the Connection phase III RCT conducted in 598
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placebo, no effect of latrepirdine was shown after 26 weeks on the
ADAS-cog, on the MMSE scores or on the ADCS-ADL [60]. A phase III
multicenter, randomized, placebo-controlled, double-blind twelve-
month safety and efﬁcacy study with latrepirdine vs placebo is ongoing
in patients with mild-to-moderate AD on donepezil (Concert study)
with ADAS-cog and ADCS-ADL as primary endpoints [clinicaltrials.gov
NCT00829374].
2.6. Ubiquinone
Another mitochondrial targeted antioxidant is coenzyme Q10 or
ubiquinone, a necessary component of the mitochondrial respiratory
chain that transports electrons from complex I (NADH-ubiquinone
reductase) and II (succinate-ubiquinone reductase) and from the ox-
idation of fatty acid and branched-chain aminoacids to complex III
(ubiquinol-cytochrome c reductase) [61]. Ubiquinone is the only lipo-
philic antioxidant endogenously synthesized and is able to efﬁciently
prevent protein oxidation, lipid peroxidation and the oxidation of
DNA, especially of mitochondrial DNA. Also, the reduced form of co-
enzyme Q10 regenerates α-tocopherol from the α-tocopheroxyl rad-
ical by interfering with the initiation and propagation step of lipid
peroxidation. It preserves mitochondrial membrane potential during
oxidative stress and protects neuronal cells against β-amyloid toxicity
through inhibition of the opening of the mitochondrial membrane
transition pore [62, 63]. The Alzheimer's Disease Cooperative Study
started in 2006 a phase I investigation to evaluate the safety, tolera-
bility and impact on biomarkers of antioxidant treatment of mild to
moderate AD. Seventy-ﬁve patients with AD underwent treatment
with either coenzyme Q 400 mg or vitamin E 800 IU plus vitamin C
200 mg plus α-lipoic acid 600 mg or placebo three times a day [clin-
icaltrials.gov NCT00117403]. The primary endpoint were changes in
CSF biomarkers after 4 months therapy and secondary outcome mea-
sures were the CSF levels of β-amyloid 40 and β-amyloid 42. No re-
sults of this trial are available up to date.
2.7. Lipoic acid
Lipoic acid, is the coenzyme of mitochondrial pyruvate dehydro-
genase and α-ketoglutarate dehydrogenase and exerts powerful mi-
tochondrial antioxidant activity by recycling other antioxidants such
as vitamin E, vitamin C and glutathione, scavenging lipid peroxidation
products and ROS and by chelating redox-active transition metals
[64]. Lipoic acid supplementation reduces memory loss and appears
to stabilize cognitive function [65, 66]. A phase I/II RCT with the aim of
treating 100 patients with AD with 600 mg lipoic acid plus 3 g ﬁsh oil
concentrate versus placebo for 18 months is ongoing [clinicaltrials.gov
NCT01058941].
2.8. Idebenone
Idebenone is a synthetic analog of coenzyme Q10 and has shown
neuronal protection against β-amyloid toxicity [67]. Treatment with
idebenone in AD in RCTs showed either signiﬁcant improvement in
behavior, memory and attention [68] or dose-dependent slowing of
disease progression for up to 2 years [69, 70] with a statistical im-
provement of ADAS-cog scores after 6 months [71]. The last published
results on idebenone treatment in AD are available from a one-year
multicentre, double-blind, placebo-controlled RCT conducted on 536
patients with mild to moderate AD. Patients were randomized to re-
ceive either120 mg, 240 mg, 360 mg idebenone or placebo t.i.d.,
with the primary endpoint of changes on the ADAS-cog and the Clin-
ical Global Impression of Change (CGIC) scales. No changes were ob-
served among groups in the primary endpoints or in the secondary
outcome measures that included activities of daily living and MMSE
[72].2.9. Ginkgo biloba
Extracts of the leaves of the maidenhair tree, G. biloba, have long
been used in China as a traditional medicine for various disorders.
Its standardized extract EGb 761® has been widely used in Europe
to improve memory and concentration problems. The mechanisms
of action are related to those of the various substances contained in
G. biloba, and include vasodilation, improvement of neurotransmis-
sion and antioxidant activity [73].
A recent Cochrane review of 36 randomized clinical trials on the
effects of G. biloba in dementia and cognitive impairment judged
most of them not valuable because of low quality, conducted in too
small population or too short in time of intervention. Nine trials of
six months duration (2016 patients) were selected. These trials tested
the same standardized preparation of G. biloba, EGb 761, at higher or
lower doses and showed inconsistent results for cognition, activities
of daily living, mood, depression and carer burden. The reviewers
concluded that the evidence that G. biloba has predictable and clini-
cally signiﬁcant beneﬁt for people with dementia or cognitive impair-
ment is inconsistent and unreliable [74].
So, to better understand the role of G. biloba in preventing memo-
ry decline along with age two intervention studies have been recently
proposed on large populations observed for a long time.
The Ginkgo Evaluation of Memory Study (GEMS), a randomized con-
trolled trial ofG. biloba in 3069 elderly persons aged>75 years, was pur-
posely designed to determinewhether G. biloba slows the rates of global
or domain-speciﬁc cognitive decline in older adults [75]. The study
found no effects on all-cause dementia, on AD or on the rate of progres-
sion to dementia in elderly persons with mild cognitive impairment
[76]. Polypharmacy was common in GEMS: nearly 75% of participants
used at least one prescription medication and one dietary supplement,
and a third used≥3 dietary supplements plus≥3 prescription medica-
tions, posing risks of adverse drug interactions.
In the GuidAge study, a total of 4066 subjects, aged 70 years or
older and reporting memory complaints were screened for participa-
tion. 2854 fulﬁlled the eligibility criteria to be treated with 120 mg
EGb twice a day or placebo for ﬁve years with the primary endpoint
of determining the rate of conversion from memory complaints to
AD using survival analysis [77]. No results are available yet.2.10. N-acetyl cysteine
N-acetyl cysteine (NAC) is a thiol-containing compound able to in-
terfere with redox transition of thiols, to modulate redox signaling, to
reduce lipid peroxidation and to act as a substrate for the synthesis of
GSH, one of the major intracellular antioxidant compounds [78]. In
addition to the antioxidant properties NAC protects against β-amyloid
toxicity through anti-apoptotic signaling pathways [79]. The NAC-003
P.L.U.S. Program(Progress through LearningUnderstanding and Support)
planned to enroll 800 subjects with earlymemory impairment who have
been prescribed CerefolinNAC daily. This is an orally administered cap-
sule containing N-acetyl cysteine associated to methycobalamin and L-
methylfolate calcium. The study has the primary objective of determining
the effect of CerefolinNAC on quality of life as assessed by the Quality of
Life Alzheimer's disease scale (QOL-AD) after 12 weeks of treatment. It
should end in May 2012 [clinicaltrials.gov NCT01370954].
A study with a nutriceutical formulation (Memory XL) containing
N-acetyl cysteine added to folic acid, vitamin B12, vitamin E (as α-
tocopherol), S-adenosylmethionine and acetyl-L-carnitine was recently
completed in 60 subjects with MCI treated for one year to evaluate
the effect on the cognitive and behavioral status [clinicaltrials.gov
NCT00903695].Another large multi-site placebo-controlled clinical
trial with Memory XL is recruiting patients with AD or subjects with
MCI to determine whether or not this formulation can be protective
and delay MCI conversion to AD [clinicaltrials.gov NCT01320527].
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Oxidative stress is a well established pathophysiological factor in
AD but up to now use of antioxidants in prevention or therapy gave
conﬂicting results.
One possible explanation is related to the low permeability of the
blood brain barrier to most of the antioxidants currently used. New
delivery systems, such as those based on nanoparticles, might repre-
sent a successful strategy for drug delivery into CNS [80].
Another important topic is the still unknown ﬁne tuned equilibri-
um among different antioxidants and free radical production. Use of
one single molecule, its correct therapeutic dosage, the lack of knowl-
edge of the antioxidant status of each subject undergoing the treatment
are all potentially unconsidered aspects. It is conceivable that the use of
multiple antioxidants, supported by measurements of biomarkers
reﬂecting the antioxidant status of patients, can lead to more positive
results.
Finally, the role of vascular factors in AD pathogenesis as mediated
by oxidative stress must be also taken into account. After the initial
ground-breaking epidemiological surveys indicating the high prevalence
of vascular risk factors in AD [81, 82], Vagnucci and Li [83] proposed the
hypothesis that AD pathogenesis can be mediated by altered angiogene-
sis due to a vicious circle inwhichROS generated byβ-amyloid are able to
damage brain endothelium that, in turn, reacts through thrombogenesis
and ROS production inducing more Aβ. Different agents tested for the
treatment of ADwere suggested to be associated with improved vascu-
lar NO function [2]. This is not a minor issue, as AD-associated cerebral
hypoperfusion may act as a central factor strongly linked to abnormal
NO production and oxidative stress pathways [84]. Vascular disorders
like hypertension, diabetes and atherosclerosis – frequently observed in
patients with to AD – are known to cause ischemia- and inﬂammation-
related oxidative stress. Neuronal mitochondria, that are particularly vul-
nerable to vascular oxidative damage in AD, undergo a series of
oxidation-mediated events with alterations of structure and function
[85]. Independently to the grade of importance that oxidative stress has
got among different pathogenetic hypotheses, free radical production
does play a critical role in vascular diseases and in AD and even more
so in their combination [86, 87]. Thismight be an aspect deserving further
research by comparing nutritional,micronutrient, and antioxidant strate-
gies to single-targeted strategies such as cholesterol or blood pressure
reduction in prevention of dementia. In fact the majority of clinical trials
with antioxidant supplements have been often conductedwithout taking
into account the role of vascular factors. Furthermore, in some trials, pres-
ence of vascular risk factors constituted an exclusion criterion for the
study.
Other limits of trials with antioxidants in AD are due to the study
design itself, including type of antioxidant and time window vs. nat-
ural nutrition, lack of previously established efﬁcacy on oxidative
stress biomarkers, lack of nutritional information, lack of well estab-
lished neuropsychological measures and lifestyle endpoints, different
disease severity [88].
So, it is critical that new diagnostic recommendations for mild cogni-
tive impairment and AD [89, 90] are promptly used to ensure a homoge-
neous scientiﬁc clinical approach to upcoming studies. Observational,
cross-sectional studies aimed at identifying outcomes whose changes
are possibly inﬂuenced by targeted therapies should use themost possi-
bly homogeneous tools. For example, a recent systematic review of 39
RCTs using supplemental micronutrients or phytochemicals in cognitive
impairment found that 121 different tasks were used across studies to
verify changes in cognition [91]. Also, if aging, vascular pathology and
risk factors as well as oxidative stress and lifestyle-related factors play
such a critical role in AD, new clinical trials with antioxidants need to
be designed taking all these factors into account. Finally, preventive
strategies against cognitive impairment and dementia are likely the irre-
placeable tools to effectively reduce AD burden. If about 23 million of the
globally expected 106 million AD cases by 2050 were to be avoidedcompletely if it had been possible to delay AD start by two years starting
in 2010 [92], it is time that practical approaches including the use of de-
mentia risk indices [93] and the early detection of cardiovascular risk fac-
tors aimed at their drastic reduction [94] become real part of anti-AD
strategies.
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